Nykredit A/S’s BridgeBio Pharma BBIO Stock Holding History

Nykredit A/S’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$410K	Buy	+5,510	New	+$386K	﹤0.01%	745

Other funds holding BBIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Nykredit A/S's BBIO Position: Q2 2026 in Review

Nykredit A/S opened a new position in BridgeBio Pharma (BBIO) in Q2 2026: 5,510 shares worth $410K. The stake represents ﹤0.01% of the portfolio and ranks #745 among its holdings.

330 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Nykredit A/S held 5,510 shares of BridgeBio Pharma worth $410K as of Q2 2026.
BridgeBio Pharma was a new Nykredit A/S position in Q2 2026.
BridgeBio Pharma made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #745 holding.
330 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.